-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers from Queen Mary University of London have developed a new method for treating heart disease in patients with rheumatoid arthritis (RA)
Currently, patients with rheumatoid arthritis are particularly susceptible to a heart defect called diastolic dysfunction, which can lead to heart failure, leading to a higher mortality rate in this patient population
The new study, published in the Proceedings of the National Academy of Sciences (PNAS), addresses this unmet clinical need by developing an experimental model of cardiomyopathy in inflammatory arthritis
After several attempts, the research team at the William Harvey Institute (WHRI) at Queen Mary’s College successfully identified the correct model by describing experimental animals suffering from arthritis
The lead author of the study, Professor Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London, said: "Usually, the description of effective models of the disease can open up new prospects for pathogenic mechanisms and new treatments
Original search:
DOI
10.
Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis
